↓ Skip to main content

RNA Vaccines

Overview of attention for book
Cover of 'RNA Vaccines'

Table of Contents

  1. Altmetric Badge
    Book Overview
  2. Altmetric Badge
    Chapter 1 Introduction to RNA Vaccines.
  3. Altmetric Badge
    Chapter 2 Self-Replicating RNA.
  4. Altmetric Badge
    Chapter 3 Self-Replicating RNA Vaccine Delivery to Dendritic Cells.
  5. Altmetric Badge
    Chapter 4 Plant Expression of Trans-Encapsidated Viral Nanoparticle Vaccines with Animal RNA Replicons.
  6. Altmetric Badge
    Chapter 5 RNActive® Technology: Generation and Testing of Stable and Immunogenic mRNA Vaccines.
  7. Altmetric Badge
    Chapter 6 Nucleoside Modified mRNA Vaccines for Infectious Diseases.
  8. Altmetric Badge
    Chapter 7 Generation and Evaluation of Prophylactic mRNA Vaccines Against Allergy.
  9. Altmetric Badge
    Chapter 8 Measuring the Adjuvant Activity of RNA Vaccines.
  10. Altmetric Badge
    Chapter 9 Generation of Immunostimulating 130 nm Protamine-RNA nanoparticles.
  11. Altmetric Badge
    Chapter 10 Electroporation of mRNA as Universal Technology Platform to Transfect a Variety of Primary Cells with Antigens and Functional Proteins.
  12. Altmetric Badge
    Chapter 11 Adjuvant-Enhanced mRNA Vaccines.
  13. Altmetric Badge
    Chapter 12 Enhanced Delivery of DNA or RNA Vaccines by Electroporation.
  14. Altmetric Badge
    Chapter 13 The European Regulatory Environment of RNA-Based Vaccines.
  15. Altmetric Badge
    Chapter 14 Discovery and Subtyping of Neo-Epitope Specific T-Cell Responses for Cancer Immunotherapy: Addressing the Mutanome.
  16. Altmetric Badge
    Chapter 15 Considerations for Producing mRNA Vaccines for Clinical Trials.
  17. Altmetric Badge
    Chapter 16 Nonclinical Safety Testing of RNA Vaccines.
  18. Altmetric Badge
    Chapter 17 Immunotherapy of Uveal Melanoma: Vaccination Against Cancer.
Attention for Chapter 3: Self-Replicating RNA Vaccine Delivery to Dendritic Cells.
Altmetric Badge

About this Attention Score

  • Good Attention Score compared to outputs of the same age (68th percentile)
  • High Attention Score compared to outputs of the same age and source (84th percentile)

Mentioned by

twitter
1 tweeter
wikipedia
4 Wikipedia pages

Citations

dimensions_citation
10 Dimensions

Readers on

mendeley
43 Mendeley
You are seeing a free-to-access but limited selection of the activity Altmetric has collected about this research output. Click here to find out more.
Chapter title
Self-Replicating RNA Vaccine Delivery to Dendritic Cells.
Chapter number 3
Book title
RNA Vaccines
Published in
Methods in molecular biology, January 2017
DOI 10.1007/978-1-4939-6481-9_3
Pubmed ID
Book ISBNs
978-1-4939-6479-6, 978-1-4939-6481-9
Authors

Thomas Démoulins, Pavlos C. Englezou, Panagiota Milona, Nicolas Ruggli, Nicola Tirelli, Chantal Pichon, Cédric Sapet, Thomas Ebensen, Carlos A. Guzmán, Kenneth C. McCullough, Démoulins, Thomas, Englezou, Pavlos C., Milona, Panagiota, Ruggli, Nicolas, Tirelli, Nicola, Pichon, Chantal, Sapet, Cédric, Ebensen, Thomas, Guzmán, Carlos A., McCullough, Kenneth C.

Editors

Thomas Kramps, Knut Elbers

Abstract

Most current vaccines are either inactivated pathogen-derived or protein/peptide-based, although attenuated and vector vaccines have also been developed. The former induce at best moderate protection, even as multimeric antigen, due to limitations in antigen loads and therefore capacity for inducing robust immune defense. While attenuated and vector vaccines offer advantages through their replicative nature, drawbacks and risks remain with potential reversion to virulence and interference from preexisting immunity. New advances averting these problems are combining self-amplifying replicon RNA (RepRNA) technology with nanotechnology. RepRNA are large self-replicating RNA molecules (12-15 kb) derived from viral genomes defective in at least one structural protein gene. They provide sustained antigen production, effectively increasing vaccine antigen payloads over time, without the risk of producing infectious progeny. The major limitation with RepRNA is RNase-sensitivity and inefficient uptake by dendritic cells (DCs)-absolute requirements for efficacious vaccine design. We employed biodegradable delivery vehicles to protect the RepRNA and promote DC delivery. Encapsulating RepRNA into chitosan nanoparticles, as well as condensing RepRNA with polyethylenimine (PEI), cationic lipids, or chitosans, has proven effective for delivery to DCs and induction of immune responses in vivo.

Twitter Demographics

The data shown below were collected from the profile of 1 tweeter who shared this research output. Click here to find out more about how the information was compiled.

Mendeley readers

The data shown below were compiled from readership statistics for 43 Mendeley readers of this research output. Click here to see the associated Mendeley record.

Geographical breakdown

Country Count As %
Unknown 43 100%

Demographic breakdown

Readers by professional status Count As %
Researcher 12 28%
Student > Ph. D. Student 6 14%
Student > Master 5 12%
Student > Bachelor 4 9%
Other 3 7%
Other 3 7%
Unknown 10 23%
Readers by discipline Count As %
Agricultural and Biological Sciences 7 16%
Biochemistry, Genetics and Molecular Biology 6 14%
Immunology and Microbiology 5 12%
Pharmacology, Toxicology and Pharmaceutical Science 3 7%
Chemistry 2 5%
Other 8 19%
Unknown 12 28%

Attention Score in Context

This research output has an Altmetric Attention Score of 4. This is our high-level measure of the quality and quantity of online attention that it has received. This Attention Score, as well as the ranking and number of research outputs shown below, was calculated when the research output was last mentioned on 21 June 2020.
All research outputs
#5,245,562
of 18,719,001 outputs
Outputs from Methods in molecular biology
#1,464
of 10,608 outputs
Outputs of similar age
#122,106
of 400,970 outputs
Outputs of similar age from Methods in molecular biology
#242
of 1,614 outputs
Altmetric has tracked 18,719,001 research outputs across all sources so far. This one has received more attention than most of these and is in the 70th percentile.
So far Altmetric has tracked 10,608 research outputs from this source. They receive a mean Attention Score of 3.1. This one has done well, scoring higher than 85% of its peers.
Older research outputs will score higher simply because they've had more time to accumulate mentions. To account for age we can compare this Altmetric Attention Score to the 400,970 tracked outputs that were published within six weeks on either side of this one in any source. This one has gotten more attention than average, scoring higher than 68% of its contemporaries.
We're also able to compare this research output to 1,614 others from the same source and published within six weeks on either side of this one. This one has done well, scoring higher than 84% of its contemporaries.